InsidersTradesSigma
申报总数
公司
▲ 买入（0 笔）
▼ 卖出（5 笔）
内部人交易记录
首席执行官已披露买入
0
已披露卖出
5
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Browse the detailed record of transactions filed by Accardi Mario Alberto, President, Orexin Program. Director active across 1 company, notably Centessa Pharmaceuticals plc. Aggregated, 14 disclosures have been published. Breakdown: 0 buy · 5 sells. Total volume traded: €505k. History available since 24 June 2025. The latest transaction was filed on 1 February 2026 (Retenue fiscale). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Accardi Mario Alberto
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报14 总计
243,282 股Ordinary SharesSEC:0001470831-26-000616:0
2,915 股@ US$24.579.9% 占其流量Ordinary SharesSEC:0001470831-26-000088:0
68,000 股0Ordinary SharesSEC:0001470831-26-000088:1
7,432 股@ US$28.69830.3% 占其流量Ordinary SharesSEC:0001470831-25-000390:0
2,568 股@ US$29.207710.6% 占其流量Ordinary SharesSEC:0001470831-25-000390:1
5,000 股@ US$9.530.0007% mcap27.2% 占其流量Ordinary SharesSEC:0001470831-25-000388:0
593 股@ US$24.901.7% 占其流量Ordinary SharesSEC:0001470831-25-000288:0
5,000 股@ US$8.010.0006% mcap22.8% 占其流量Ordinary SharesSEC:0001470831-25-000273:0
7,430 股@ US$21.333322.1% 占其流量Ordinary SharesSEC:0001470831-25-000208:0
742 股@ US$22.02132.3% 占其流量Ordinary SharesSEC:0001470831-25-000208:1
5,000 股@ US$8.014.7% 占其流量Ordinary SharesSEC:0001470831-25-000187:0
597 股@ US$17.171.3% 占其流量Ordinary SharesSEC:0001847903-25-000127:0
8,322 股@ US$15.230815.7% 占其流量Ordinary SharesSEC:0001847903-25-000125:0
15,000 股@ US$3.858.6% 占其流量Ordinary SharesSEC:0001847903-25-000113:0
14 条申报中的 14 条
About Accardi Mario Alberto
Mario Alberto Accardi is the President of the Orexin Program at Centessa Pharmaceuticals plc. In this role, he is responsible for the strategic and operational direction of the program, aiming to develop innovative treatments. His expertise in the pharmaceutical field is essential for advancing the company's goals and improving patient outcomes.
